AletheiaHQ
DIR-A9-2AT-30X0/LVL 1·Quick WinRepetitive, ultra-low-risk data capture. No judgment required. Examples: scraping a 500-page municipal budget to extract micro-grant recipients; submitting a FOIA request for raw government maintenance logs; building a niche data directory from public sources./90% confidence
Return to Directory

Map SBIR Biotech IP Ownership via Public Patent & FOIA Data

Organization
NSF SBIR program's lack of transparent IP ownership tracking
Sector
Pharma business development teams doing due diligence on SBIR companies
Location
Location unspecified
// Venture Capital// Journalism// Biotech// Data Scraping// Machine Learning & Modeling// IP// Open-Source Intelligence// Health Policy & Regulation

Executive Context

NSF awarded $305K SBIR Phase I grant to AICONIC BIOSCIENCES LLC for AI-assisted gene therapy platform targeting hearing disorders, creating an 18-month research validation period ending Dec 2027 with no automatic commercialization pathway. The structural discontinuity between academic validation and market deployment represents a $350M revenue opportunity trapped by institutional design constraints.

Catalyst / Timing

NSF publishes award amounts but not the underlying IP ownership structure or technical validation data. Pharma BD teams need to know if AICONIC actually owns its AI-gene therapy platform or is just licensing university IP - a critical due diligence gap.

Projected Yield

$5,000-15,000 per dataset sale to pharma BD teams

Structural Friction

• Vulnerability: NSF publishes award amounts but not the underlying IP ownership structure or technical validation data. Pharma BD teams need to know if AICONIC actually owns its AI-gene therapy platform or is just licensing university IP - a critical due diligence gap. • Capital yield: $5,000-15,000 per dataset sale to pharma BD teams • Resource capture: Proprietary database linking 100+ SBIR companies to their exact IP ownership structures • Influence capture: First-mover authority on SBIR biotech IP intelligence • Sovereignty yield: Control of definitive IP ownership dataset for SBIR Phase I biotechs • Required vectors: Vector: Patent Research, Vector: FOIA/Public Records

Required Capabilities

  • Vector: Patent Research

    Primary executor: Phase 1: IP Ownership Reconnaissance: Search USPTO Patent Assignment Search database for assignments to 'AICONIC BIOSCIE

  • Vector: FOIA/Public Records

    Supporting vector for: Map SBIR Biotech IP Ownership via Public Patent & FOIA Data

Execution Protocol

Execution Protocol Locked

A one-time payment of $19 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.